Exploring and exploiting metabolic plasticity in regulatory T cells

探索和利用调节性 T 细胞的代谢可塑性

基本信息

项目摘要

PROJECT ABSTRACT Regulatory T (Treg) cells represent key cellular players in the immune response, tasked with maintaining balance in immunity. Endowed with potent suppressive function, Treg cells maintain immune homeostasis, prevent autoimmunity, and curtail robust immune responses to prevent collateral tissue damage. These cells are critically important, and their insufficiency or loss results in autoimmunity. However, they can also be over- activated, preventing effective immunity to chronic viral infections and cancer. We and others hypothesize that Treg cells differ from conventional T cells not only in their function, but also in how they fuel that function. The intersection of metabolism and immunity has been of immense recent interest; our laboratory studies how energetics impacts immune cell function with a focus on immunity in the tumor microenvironment. We hypothesize that, as regulatory T cells exist out-of-sync with their conventional counterparts, suppressing autoimmunity or curtailing productive immunity in the tissues, they exhibit metabolic plasticity, able to persist and thrive on alternative metabolic substrates in the environment. Our preliminary studies support this hypothesis, using cancer as a model. Tumor-infiltrating Treg cells are extraordinarily active and proliferative, and maintain their epigenetic and lineage stability despite substantial inflammatory insults and thus represent a model of an exemplary regulatory cell. We have found that Treg cells `stratify' into distinct metabolic subsets with different suppressive capacities. This New Innovator project seeks to understand how the microenvironment, in cancer and in other diseases, promotes Treg cell function through metabolic symbiosis. We present evidence of alternative metabolic pathways utilizing byproducts of tumor cell metabolism that may support Treg cell function in the tissues. We will explore, based on transcriptomic profiles of these cells, which metabolites present in the tumor microenvironment support Treg cell function and epigenetic stability. Further, we have developed a novel system by which certain metabolic pathways can be enforced in a Treg cell-specific manner. Taken together, these studies will shed light on how these crucial cells are exploited by cancer to evade the immune response but also open up potential avenues by which these cells may be therapeutically modulated through metabolic means to prevent autoimmunity or promote the anti-tumor response in cancer.
项目摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Greg M. Delgoffe其他文献

Regulatory T cell stability is maintained by a neuropilin-1 : semaphorin-4 a axis
调节性 T 细胞的稳定性由 Neuropilin-1 : semaphorin-4 a 轴维持
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Greg M. Delgoffe;Seng;Meghan E. Turnis;D. Gravano;C. Guy;Abigail E. Overacre;M. Bettini;P. Vogel;D. Finkelstein;Jody;Bonnevier;C. Workman;D. Vignali
  • 通讯作者:
    D. Vignali
The intrinsic pro-tumorigenic role of IRF1
IRF1 的内在促肿瘤作用
  • DOI:
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Lulu Shao;W. Hou;Nicole E. Scharping;Greg M. Delgoffe;Saumendra N. Sarkar
  • 通讯作者:
    Saumendra N. Sarkar
Redox and detox: Malate shuttle metabolism keeps exhausted T cells fit.
氧化还原和排毒:苹果酸穿梭代谢使疲惫的 T 细胞保持健康。
  • DOI:
    10.1016/j.cmet.2023.11.005
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    29
  • 作者:
    Alok Kumar;Greg M. Delgoffe
  • 通讯作者:
    Greg M. Delgoffe
Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function
富含肿瘤间质液的磷酸乙醇胺抑制 T 细胞功能
  • DOI:
    10.1038/s41556-025-01650-9
  • 发表时间:
    2025-04-21
  • 期刊:
  • 影响因子:
    19.100
  • 作者:
    Yupeng Wang;Drew Wilfahrt;Patrick Jonker;Konstantinos Lontos;Chufan Cai;Benjamin Cameron;Bingxian Xie;Ronal M. Peralta;Emerson R. Schoedel;William G. Gunn;Roya AminiTabrizi;Hardik Shah;Dayana B. Rivadeneira;Alexander Muir;Greg M. Delgoffe
  • 通讯作者:
    Greg M. Delgoffe
435 A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma
435 纳武单抗联合阿西替尼治疗抗 PD1 难治性晚期黑色素瘤患者的 II 期试验
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    10.9
  • 作者:
    Saba S. Shaikh;Y. Zang;Hong Wang;Xi Yang;C. Sander;Amy Rose;D. Davar;J. Luke;H. Zarour;J. Kirkwood;Greg M. Delgoffe;Y. Najjar
  • 通讯作者:
    Y. Najjar

Greg M. Delgoffe的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Greg M. Delgoffe', 18)}}的其他基金

Dissecting the role of hypoxia in T cell differentiation in cancer
剖析缺氧在癌症 T 细胞分化中的作用
  • 批准号:
    10578000
  • 财政年份:
    2023
  • 资助金额:
    $ 230.11万
  • 项目类别:
Metabolic control of regulatory T cell functional identity
调节性 T 细胞功能特性的代谢控制
  • 批准号:
    10510537
  • 财政年份:
    2022
  • 资助金额:
    $ 230.11万
  • 项目类别:
Uncovering the metabolic underpinnings of T cell exhaustion
揭示 T 细胞耗竭的代谢基础
  • 批准号:
    10707255
  • 财政年份:
    2022
  • 资助金额:
    $ 230.11万
  • 项目类别:
Metabolic control of regulatory T cell functional identity
调节性 T 细胞功能特性的代谢控制
  • 批准号:
    10677731
  • 财政年份:
    2022
  • 资助金额:
    $ 230.11万
  • 项目类别:
Uncovering the metabolic underpinnings of T cell exhaustion
揭示 T 细胞耗竭的代谢基础
  • 批准号:
    10593593
  • 财政年份:
    2022
  • 资助金额:
    $ 230.11万
  • 项目类别:
Elucidating the regulation of interleukin-35, a regulatory cytokine, in T cells
阐明 T 细胞中调节性细胞因子 IL-35 的调节
  • 批准号:
    8255282
  • 财政年份:
    2012
  • 资助金额:
    $ 230.11万
  • 项目类别:
Elucidating the regulation of interleukin-35, a regulatory cytokine, in T cells
阐明 T 细胞中调节性细胞因子 IL-35 的调节
  • 批准号:
    8610875
  • 财政年份:
    2012
  • 资助金额:
    $ 230.11万
  • 项目类别:
Elucidating the regulation of interleukin-35, a regulatory cytokine, in T cells
阐明 T 细胞中调节性细胞因子 IL-35 的调节
  • 批准号:
    8432601
  • 财政年份:
    2012
  • 资助金额:
    $ 230.11万
  • 项目类别:
Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)
项目 1:缺氧和代谢失调作为头颈鳞状细胞癌 (HNSCC) 免疫治疗的目标障碍
  • 批准号:
    10331957
  • 财政年份:
    2004
  • 资助金额:
    $ 230.11万
  • 项目类别:
Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)
项目 1:缺氧和代谢失调作为头颈鳞状细胞癌 (HNSCC) 免疫治疗的目标障碍
  • 批准号:
    10704505
  • 财政年份:
    2004
  • 资助金额:
    $ 230.11万
  • 项目类别:

相似海外基金

B cell development, autoimmunity and immune regulation
B 细胞发育、自身免疫和免疫调节
  • 批准号:
    MR/Y033701/1
  • 财政年份:
    2024
  • 资助金额:
    $ 230.11万
  • 项目类别:
    Research Grant
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
  • 批准号:
    502578
  • 财政年份:
    2024
  • 资助金额:
    $ 230.11万
  • 项目类别:
Applying advanced understanding of CTLA-4 function to optimise therapies for autoimmunity
应用对 CTLA-4 功能的深入理解来优化自身免疫疗法
  • 批准号:
    MR/Y001273/1
  • 财政年份:
    2024
  • 资助金额:
    $ 230.11万
  • 项目类别:
    Research Grant
MUC16 (CA125) mutations promote fibrosis and autoimmunity in systemic sclerosis
MUC16 (CA125) 突变促进系统性硬化症的纤维化和自身免疫
  • 批准号:
    478933
  • 财政年份:
    2023
  • 资助金额:
    $ 230.11万
  • 项目类别:
    Operating Grants
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
新发自身免疫/纵向免疫系统分析(MONA-LISA)的机制
  • 批准号:
    10655219
  • 财政年份:
    2023
  • 资助金额:
    $ 230.11万
  • 项目类别:
Development of serologic test for early risk stratification of islet autoimmunity in genetically predisposed T1D individuals
开发用于遗传易感性 T1D 个体胰岛自身免疫早期风险分层的血清学检测
  • 批准号:
    10760885
  • 财政年份:
    2023
  • 资助金额:
    $ 230.11万
  • 项目类别:
Autoimmunity-Associated B Cells in Lupus Nephritis
狼疮性肾炎中自身免疫相关的 B 细胞
  • 批准号:
    10582053
  • 财政年份:
    2023
  • 资助金额:
    $ 230.11万
  • 项目类别:
Understanding autoimmunity: Why do B cells sometimes attack our tissues instead of protecting us from infections?
了解自身免疫:为什么 B 细胞有时会攻击我们的组织而不是保护我们免受感染?
  • 批准号:
    2889164
  • 财政年份:
    2023
  • 资助金额:
    $ 230.11万
  • 项目类别:
    Studentship
Heparan sulfate as a platform to boost regulatory T cell suppression of autoimmunity
硫酸乙酰肝素作为增强调节性 T 细胞抑制自身免疫的平台
  • 批准号:
    490663
  • 财政年份:
    2023
  • 资助金额:
    $ 230.11万
  • 项目类别:
    Operating Grants
The interplay of sex hormones and chromosomes dictates pathogenicity in progressive CNS autoimmunity.
性激素和染色体的相互作用决定了进行性中枢神经系统自身免疫的致病性。
  • 批准号:
    488982
  • 财政年份:
    2023
  • 资助金额:
    $ 230.11万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了